Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Receivables (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Change in Receivables for 14 consecutive years, with $27.9 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 9.18% to $27.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.5 million through Dec 2025, up 177.56% year-over-year, with the annual reading at $58.5 million for FY2025, 177.56% up from the prior year.
  • Change in Receivables hit $27.9 million in Q4 2025 for Ani Pharmaceuticals, up from $27.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $27.9 million in Q4 2025 to a low of -$16.8 million in Q4 2023.
  • Historically, Change in Receivables has averaged $5.9 million across 5 years, with a median of $4.3 million in 2022.
  • Biggest five-year swings in Change in Receivables: skyrocketed 2333.29% in 2022 and later crashed 253.66% in 2024.
  • Year by year, Change in Receivables stood at -$5.4 million in 2021, then surged by 565.38% to $25.0 million in 2022, then crashed by 167.04% to -$16.8 million in 2023, then soared by 252.2% to $25.5 million in 2024, then increased by 9.18% to $27.9 million in 2025.
  • Business Quant data shows Change in Receivables for ANIP at $27.9 million in Q4 2025, $27.0 million in Q3 2025, and $5.5 million in Q2 2025.